SiBone (SIBN) Stock Price, News & Analysis

Company Overview

SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on developing and commercializing solutions for disorders of the sacroiliac joint and pelvic region. Its products are designed to support minimally invasive procedures that stabilize the sacroiliac joint and address sacroiliac joint dysfunction, degeneration, and related conditions.

The company’s portfolio includes the iFuse Implant System, iFuse-3D implants, iFuse-TORQ implants, and the iFuse Bedrock Granite system for sacroiliac joint fusion and pelvic fixation. SI-BONE also offers related surgical instruments and technologies intended to assist surgeons with implant placement and procedural workflow.

Founded in 2008, SI-BONE serves orthopedic and spine specialists through commercial operations in the United States and selected international markets. The company’s products are used in hospitals and other surgical settings for procedures involving the sacroiliac joint and adjacent pelvic anatomy.

Key Stats

• Today's Range: $18.94 to $19.27
• 50-Day Range: $16.47 to $19.96
• 52-Week Range: $11.48 to $21.89
• Volume: 18,057 shs
• Average Volume: 609,608 shs
• Market Capitalization: $846.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.17
• Consensus Rating: Moderate Buy

SiBone Stock Analysis - MarketRank™

SiBone scored higher than 49% of companies evaluated by MarketBeat, and ranked 501st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SiBone has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

SiBone has a consensus price target of $24.17, representing about 26.2% upside from its current price of $19.15.

Amount of Analyst Coverage

SiBone has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SiBone are expected to grow in the coming year, from ($0.40) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SiBone is -56.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SiBone is -56.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SiBone has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.89% of the float of SiBone has been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 10.65, which indicates bearish sentiment.

Change versus previous month

Short interest in SiBone has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SiBone does not currently pay a dividend.

Dividend Growth

SiBone does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.81

News Sentiment

SiBone has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for SiBone this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,193,690.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of SiBone is held by insiders.

Percentage Held by Institutions

98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:SIBN
• CIK: 1459839
• Web: www.si-bone.com
• Phone: (408) 207-0700
• Fax: N/A
• Employees: 376
• Year Founded: 2008

Price Target and Rating

• Average Price Target for SiBone: $24.17
• High Price Target: $27.00
• Low Price Target: $20.00
• Potential Upside/Downside: +26.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.90 million
• Net Margins: -6.85%
• Pretax Margin: -6.85%
• Return on Equity: -8.23%
• Return on Assets: -6.07%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 9.15
• Quick Ratio: 7.55

Sales & Book Value

• Annual Sales: $213.60 million
• Price / Sales: 3.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 4.68

Miscellaneous

• Outstanding Shares: 44,349,000
• Free Float: 42,575,000
• Market Cap: $849.28 million
• Optionable: Optionable
• Beta: 0.70